CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.
In a move that may reduce burnout for providers and get needed medications, such as biosimilars, into the hands of patients faster and with less hassle, CMS has established a new policy on prior authorizations and the electronic exchange of health information.
The system sets deadlines for payers to approve or deny urgent requests for health care, requires them to provide reasons for their decisions, and incorporates the use of electronic interface applications that facilitate the communication of health records information between providers and payers.
Seema Verma, administrator of CMS, has described the “new rule” as a departure from “Stone Age” reliance on fax machines; a move that gives patients, payers, and providers ready access to patient data; and an end to “mindless nitpicking and wrangling” over patient entitlements to care.
She described the rule as “the result of numerous listening sessions with plans and providers aimed at crafting a new process that balances the need for greater efficiency and consistency in prior authorization with its important role in preventing fraud, abuse, and unnecessary expenditures.”
The new policy was developed by the Office of Burden Reduction and Health Informatics, which CMS created in June 2020 specifically to increase the efficiency of health information transfers and ease regulatory and administrative burdens faced by providers.
CMS also hopes to see a reduction in repeated requests for prior authorization and an overall reduction in health care costs.
The new CMS Interoperability and Prior Authorization rule affects Medicaid and Children’s Health Insurance Program (CHIP) managed care plans, state Medicaid and CHIP fee-for-service programs, and issuers of individual market Qualified Health Plans on the federally facilitated exchanges. These payers would have to implement software to allow the smooth flow of electronic health information about patients and assist with prior authorization.
The deadlines affecting maximum response time for prior authorization requests go into effect on January 1, 2024. For nonurgent requests, payers will have a full calendar week to respond.
“For patients, there will be no more wrangling with prior providers and locating ancient fax machines to take possession of one’s own data; for providers, there will be no more piecing together patient health histories based on incomplete, half-forgotten snippets of information pried out of the patients themselves; for payers, this is the first step towards building the important data sharing systems we need to move towards value,” Verma said.
In an American Medical Association survey last year, prior authorizations were cited as a growing burden on physicians, 91% of whom said they believe prior authorization requirements delayed patients’ access to care and 88% of whom said the burden of these requirements has increased in recent years.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.